A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome

Aminah Jatoi, Megan E. Grudem, Travis J. Dockter, Matthew S. Block, Jose C. Villasboas, Angelina Tan, Erin Deering, Pashtoon M. Kasi, Aaron S. Mansfield, Juliana Perez Botero, Scott H. Okuno, Deanne R. Smith, Alan P. Fields

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Purpose: Paclitaxel causes the paclitaxel-induced acute pain (PIAP) syndrome. Based on preclinical data, we hypothesized that the protein kinase C (PKC) iota inhibitor, auranofin (a gold salt used for other pain conditions), palliates this pain. Methods: In a randomized, double-blinded manner, patients who had suffered this syndrome were assigned a one-time dose of auranofin 6 mg orally on day #2 of the chemotherapy cycle (post-paclitaxel) versus placebo. Patients completed the Brief Pain Inventory and a pain diary on days 2 through 8 and at the end of the cycle. The primary endpoint was pain scores, as calculated by area under the curve, in response to “Please rate your pain by circling the one number that best describes your pain at its worse in the last 24 hours.” Results: Thirty patients were enrolled. For the primary endpoint, mean area under the curve of 55 units (standard deviation 19) and 61 units (standard deviation 22) were observed in auranofin-treated and placebo-exposed patients, respectively (p = 0.44). On day 8 and at the end of the cycle, pain scores in auranofin-treated patients were more favorable, although differences were not statistically significant. Conclusions: In the dose schedule studied, auranofin did not palliate the PIAP syndrome, but delayed beneficial trends suggest further study for this indication.

Original languageEnglish (US)
Pages (from-to)833-838
Number of pages6
JournalSupportive Care in Cancer
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2017

Keywords

  • Auranofin
  • Myalgias
  • Protein kinase C

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome'. Together they form a unique fingerprint.

  • Cite this